Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UM171-Expanded Cord Blood Transplantation in High Risk Acute Leukemia/Myelodysplasia
NCT04103879Phase 2Completed
- Sponsor
- ExCellThera
- Start
- Nov 2020
- Primary completion
- Feb 2026
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
A Phase 2 trial of dorocubicel in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), sponsored by ExCellThera. Started Nov 2020; status: completed.
02
Drugs
dorocubicel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT04103879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04103879.